Investigational Agent Accountability Record Forms in the Conduct of Investigational Trials in Cancer Treatment (NCI)

OMB 0925-0613

OMB 0925-0613

This information collection is a revision for a three-year period. The U.S. Food and Drug Administration (FDA) holds the National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis/Cancer Therapy Evaluation Program (NCI/DCTD/CTEP) and the Division of Cancer Prevention (DCP) responsible, as a sponsor of investigational drug trials, to assure the FDA that systems for accountability are being maintained by investigators in its clinical trials program. Data obtained from the Investigational Agent Accountability Record Forms are used to track the dispensing of investigational anticancer agents from receipt from the NCI to dispensing or administration to patients.

The latest form for Investigational Agent Accountability Record Forms in the Conduct of Investigational Trials in Cancer Treatment (NCI) expires 2022-03-31 and can be found here.

OMB Details

Financial Disclosure Form (Attachments 5A or 5B)

Federal Enterprise Architecture: Health - Health Care Services

Form 6Attach 5B Financial Disclosure DCPFillable FileableForm and instruction
Form 5Attach 5 Financial Disclosure FormFillable FileableForm and instruction

Review document collections for all forms, instructions, and supporting documents - including paper/printable forms.


© 2024 OMB.report | Privacy Policy